Published in J Neuroimmunol on May 01, 1993
Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci U S A (1994) 1.66
Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A (1997) 1.48
A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A (1997) 1.40
Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci U S A (1996) 1.38
Oral tolerance in disease. Gut (1999) 1.17
Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J Clin Invest (1999) 0.95
Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci U S A (2004) 0.95
Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats. Clin Exp Immunol (1998) 0.93
Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc Natl Acad Sci U S A (2000) 0.92
Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit. Proc Natl Acad Sci U S A (1999) 0.89
Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals. Clin Exp Immunol (1998) 0.88
Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest (1999) 0.87
The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci U S A (2001) 0.87
Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction. Br J Ophthalmol (2001) 0.85
High numbers of autoantigen-reactive mononuclear cells expressing interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) are present in cord blood. Clin Exp Immunol (1995) 0.77
Current and emerging treatments for the management of myasthenia gravis. Ther Clin Risk Manag (2011) 0.77
Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs. Exp Neurol (2015) 0.77
Vaccines against myasthenia gravis. Expert Opin Biol Ther (2005) 0.76
Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis. J Clin Invest (1999) 0.76
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler (1999) 4.91
Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest (1977) 4.63
The DRASIC cation channel contributes to the detection of cutaneous touch and acid stimuli in mice. Neuron (2001) 3.56
The mammalian sodium channel BNC1 is required for normal touch sensation. Nature (2000) 3.30
COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR. Clin Chem (1996) 3.17
Immunoglobulins in multiple sclerosis and infections of the nervous system. Arch Neurol (1971) 2.51
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet (1996) 2.06
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer (2004) 2.03
Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest (1977) 2.02
Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol (2011) 2.00
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer (2006) 1.96
Odontogenic tumours: a retrospective study of 1642 cases in a Chinese population. Int J Oral Maxillofac Surg (2006) 1.91
Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain (2001) 1.78
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol (1991) 1.65
Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol (2000) 1.61
Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest (1990) 1.57
Early diagnosis of tuberculous meningitis by detection of anti-BCG secreting cells in cerebrospinal fluid. Lancet (1990) 1.55
Increased incidence of Guillain-Barré syndrome postpartum. Epidemiology (1998) 1.53
Induction of kidney epithelial morphogenesis by cells expressing Wnt-1. Dev Biol (1994) 1.49
Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infect Immun (1999) 1.48
Comparison of antibodies against different viruses in cerebrospinal fluid and serum samples from patients with multiple sclerosis. Infect Immun (1974) 1.48
Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol (1994) 1.45
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood (1993) 1.45
Measles virus antibodies in multiple sclerosis. Comparison of antibody titers in cerebrospinal fluid and serum. Arch Neurol (1974) 1.44
Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest (1998) 1.44
Vitamin D and K status influences bone mineral density and bone accrual in children and adolescents with celiac disease. Eur J Clin Nutr (2011) 1.44
The B cell repertoire in experimental allergic neuritis involves multiple myelin proteins and GM1. J Neurol Sci (1994) 1.43
Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol (2000) 1.40
Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol (1996) 1.40
Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol (1973) 1.40
Ureteric bud cells secrete multiple factors, including bFGF, which rescue renal progenitors from apoptosis. Am J Physiol (1997) 1.38
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37
Isolation of additional bacteriophages with genomes of segmented double-stranded RNA. J Bacteriol (1999) 1.36
Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol (1991) 1.36
Immunoglobulins and measles antibodies in subacute sclerosing panencephalitis. Arch Neurol (1973) 1.35
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update (2011) 1.34
Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol (1994) 1.33
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia (2000) 1.31
Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res (1996) 1.30
Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol (2001) 1.30
Cerebrospinal fluid and serum immunoglobulins and antibody titers in mumps meningitis and aseptic meningitis of other etiology. Infect Immun (1978) 1.28
Stoichiometric packaging of the three genomic segments of double-stranded RNA bacteriophage phi6. Proc Natl Acad Sci U S A (1997) 1.27
Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology (1998) 1.26
Innovative mentoring programs to promote gender equity in academic medicine. Acad Med (2001) 1.23
Immunoglobulins and measles antibodies in optic neuritis. N Engl J Med (1973) 1.22
CD16- CD56+ natural killer cells after bone marrow transplantation. Blood (1992) 1.21
Characterization of antibody activity in oligoclonal immunoglobulin G synthesized within the central nervous system in a patient with tuberculous meningitis. J Clin Microbiol (1981) 1.20
Circulating CD4+CD25+ and CD4+CD25+ T cells in myasthenia gravis and in relation to thymectomy. Scand J Immunol (2004) 1.18
Multiple sclerosis: disturbed kappa: lambda chain ratio of immunoglobulin G in cerebrospinal fluid. Clin Exp Immunol (1970) 1.18
Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke (1999) 1.18
IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol (1985) 1.17
Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest (1977) 1.17
Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann Neurol (1990) 1.17
Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol (1995) 1.17
Respiratory syncytial virus stimulation of vascular endothelial cell growth Factor/Vascular permeability factor. Am J Respir Cell Mol Biol (2000) 1.17
Comparison of electrophoresis on agar gel and agarose gel in the evaluation of gamma-globulin abnormalities in cerebrospinal fluid and serum in multiple sclerosis. Clin Chim Acta (1973) 1.17
Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol (1997) 1.16
Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci (2000) 1.16
Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros. J Clin Invest (1999) 1.14
Chinese herbal medicine suxiao jiuxin wan for angina pectoris. Cochrane Database Syst Rev (2008) 1.13
Persistence of tropical ataxic neuropathy in a Nigerian community. J Neurol Neurosurg Psychiatry (2000) 1.13
Age-specific prevalence of antibody to enterotoxigenic Escherichia coli in Ecuadorian and German children. J Infect Dis (1990) 1.12
Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin Chem (1984) 1.12
Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol (1991) 1.11
Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol (2001) 1.11
In vitro packaging of individual genomic segments of bacteriophage phi 6 RNA: serial dependence relationships. J Virol (1995) 1.11
CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand (1987) 1.10
Characterization of phi 13, a bacteriophage related to phi 6 and containing three dsRNA genomic segments. Virology (2000) 1.09
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol (2011) 1.08
Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol (1999) 1.07
Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol (2012) 1.07
Increased levels of interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) mRNA expressing blood mononuclear cells in human HIV infection. Clin Exp Immunol (1994) 1.07
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol (1996) 1.07
Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol (1992) 1.07
Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J Immunol (1999) 1.06
Oligoclonal Borrelia burgdorferi-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis (1990) 1.05
Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1980) 1.05
Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.05
Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol (1998) 1.04
IL-17 and IFN-gamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat. J Neuroimmunol (2001) 1.04
Acquisition of a fourth genomic segment in bacteriophage phi 6, a bacteriophage with a genome of three segments of dsRNA. Virology (1995) 1.04
Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer (1994) 1.04
HLA haplotypes in families with high frequency of multiple sclerosis. Arch Neurol (1976) 1.04
An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry (1992) 1.04
Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplant Proc (1981) 1.03
Ischemic stroke is associated with a systemic increase of blood mononuclear cells expressing interleukin-8 mRNA. Stroke (1998) 1.02
Predominance of oligoclonal IgG type lambda in CSF in aseptic meningitis. Arch Neurol (1979) 1.02
Mechanisms of recovery from experimental allergic encephalomyelitis induced with myelin basic protein peptide 68-86 in Lewis rats: a role for dendritic cells in inducing apoptosis of CD4+ T cells. J Neuroimmunol (1999) 1.02
Oligoclonal IgG and free chains in multiple sclerosis demonstrated by thin-layer polyacrylamide gel isoelectric focusing and immunofixation. Ann Neurol (1980) 1.02
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer (2008) 1.01
Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol Scand (1994) 1.01
Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur J Immunol (1992) 1.01